Christopher Sweeney

1.1k total citations
52 papers, 361 citations indexed

About

Christopher Sweeney is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Christopher Sweeney has authored 52 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 17 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Christopher Sweeney's work include Prostate Cancer Treatment and Research (35 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Cancer Genomics and Diagnostics (9 papers). Christopher Sweeney is often cited by papers focused on Prostate Cancer Treatment and Research (35 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Cancer Genomics and Diagnostics (9 papers). Christopher Sweeney collaborates with scholars based in United States, Australia and United Kingdom. Christopher Sweeney's co-authors include Harry A. Drabkin, Saskia Neuteboom, Michael Millward, Matthew A. Spear, Andrew Spencer, David J. McConkey, Shawgi Sukumaran, Timothy Price, Amanda Townsend and Girish Sharma and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

Christopher Sweeney

45 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Sweeney United States	9	162	143	99	76	70	52	361
Cristina Fhied United States	11	111 0.7×	123 0.9×	83 0.8×	46 0.6×	61 0.9×	27	318
Bruce Keith United States	10	262 1.6×	121 0.8×	243 2.5×	86 1.1×	105 1.5×	15	504
Hiya Banerjee United States	10	83 0.5×	181 1.3×	108 1.1×	26 0.3×	38 0.5×	29	336
Christian Weißenberger Germany	8	52 0.3×	77 0.5×	106 1.1×	36 0.5×	30 0.4×	12	348
Elie A. Benaim United States	12	309 1.9×	79 0.6×	62 0.6×	45 0.6×	64 0.9×	18	411
Teresa Parli United States	9	279 1.7×	73 0.5×	96 1.0×	125 1.6×	97 1.4×	20	393
Shengkun Peng China	8	38 0.2×	119 0.8×	110 1.1×	21 0.3×	41 0.6×	18	359
Hiroaki Kawanishi Japan	8	73 0.5×	139 1.0×	123 1.2×	26 0.3×	51 0.7×	30	333
Christopher Sweeney United States	7	94 0.6×	94 0.7×	174 1.8×	22 0.3×	21 0.3×	15	285
J Alcover Spain	10	190 1.2×	97 0.7×	88 0.9×	55 0.7×	88 1.3×	29	382

Countries citing papers authored by Christopher Sweeney

Since Specialization

Citations

This map shows the geographic impact of Christopher Sweeney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Sweeney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Sweeney more than expected).

Fields of papers citing papers by Christopher Sweeney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Sweeney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Sweeney. The network helps show where Christopher Sweeney may publish in the future.

Co-authorship network of co-authors of Christopher Sweeney

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Sweeney. A scholar is included among the top collaborators of Christopher Sweeney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Sweeney. Christopher Sweeney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fisher, David J., Claire L. Vale, Larysa Rydzewska, et al.. (2025). Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).. Journal of Clinical Oncology. 43(5_suppl). 20–20. 3 indexed citations

Brown, Derek W., Hanna Tukachinsky, Jason D. Hughes, et al.. (2025). Evaluation of a variant origin prediction (VOP) algorithm to distinguish clonal hematopoiesis (CH) variants from tumor-derived variants and to predict metastatic castrate resistant prostate cancer (mCRPC) clinical responses.. Journal of Clinical Oncology. 43(5_suppl). 201–201. 1 indexed citations

Davis, Ian D., Robert Zielinski, Alastair Thomson, et al.. (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. Journal of Clinical Oncology. 42(16_suppl). 5079–5079. 3 indexed citations

Pommier, P., Wanling Xie, Praful Ravi, et al.. (2024). Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. Radiotherapy and Oncology. 201. 110532–110532.

Hamid, Anis, Jihye Park, Saud H. AlDubayan, et al.. (2024). Whole exome correlates in metastatic hormone sensitive prostate cancer (mHSPC): Results from E3805 CHAARTED.. Journal of Clinical Oncology. 42(16_suppl). 5088–5088.

Sweeney, Christopher, Chang Xu, Ryon P. Graf, et al.. (2024). Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 196–196.

Sutera, Philip, Amol C. Shetty, Yang Song, et al.. (2023). Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. European Urology Oncology. 7(2). 241–247. 6 indexed citations

Matsubara, Nobuaki, Johann S. de Bono, Christopher Sweeney, et al.. (2023). Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(2). 230–237.e1. 5 indexed citations

Sweeney, Christopher, Ryon P. Graf, David Fabrizio, et al.. (2023). Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.. Journal of Clinical Oncology. 41(6_suppl). LBA249–LBA249. 1 indexed citations

10.

Saieva, Calogero, Richard M. Lee‐Ying, Pier Vitale Nuzzo, et al.. (2023). Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.. Journal of Clinical Oncology. 41(6_suppl). 166–166. 1 indexed citations

11.

Hamid, Anis, Emily Grist, Gerhardt Attard, et al.. (2023). Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.. Journal of Clinical Oncology. 41(16_suppl). 5082–5082. 1 indexed citations

12.

Vale, Claire L., David J. Fisher, Peter J. Godolphin, et al.. (2022). Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: Meta-analysis of individual participant data from randomized trials.. Journal of Clinical Oncology. 40(16_suppl). 5070–5070. 17 indexed citations

13.

Kang, Le, Penny S. Reynolds, Bernard Fisher, et al.. (2019). Temporal map of the pig polytrauma plasma proteome with fluid resuscitation and intravenous vitamin C treatment. Journal of Thrombosis and Haemostasis. 17(11). 1827–1837. 8 indexed citations

14.

Reynolds, Penny S., Bernard Fisher, Christopher Sweeney, et al.. (2018). Interventional vitamin C: A strategy for attenuation of coagulopathy and inflammation in a swine multiple injuries model. The Journal of Trauma: Injury, Infection, and Critical Care. 85(1S). S57–S67. 19 indexed citations

15.

O’Donnell, Elizabeth, Sarah C. Markt, Rowan Miller, et al.. (2017). Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clinical Genitourinary Cancer. 16(1). 78–84. 8 indexed citations

16.

Millward, Michael, Timothy Price, Amanda Townsend, et al.. (2011). Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs. 30(6). 2303–2317. 123 indexed citations

17.

Coxon, Angela, Karen Rex, Jan Sun, et al.. (2008). Exploratory biomarkers in the HGF/SF:c-Met axis: preclinical and clinical results. Cancer Research. 68. 2804–2804. 2 indexed citations

18.

Strother, Robert Matthew & Christopher Sweeney. (2008). Lessons learned from development of docetaxel. Expert Opinion on Drug Metabolism & Toxicology. 4(7). 1007–1019. 3 indexed citations

19.

Chiorean, Elena G., Christopher Sweeney, S. Savage, et al.. (2007). Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers. Molecular Cancer Therapeutics. 6. 12 indexed citations

20.

Zhang, Shaobo, Guangyuan Zeng, Chinghai Kao, et al.. (2002). Fas‐Fas ligand signaling pathway mediates an interleukin‐12–induced rejection of a murine prostate tumor system. The Prostate. 53(1). 69–76. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact